Method for producing diphenylmethane derivative

• US 10,640,496 B2
• Filed: 06/15/2017
• Issued: 05/05/2020
• Est. Priority Date: 06/17/2016
• Status: Active Grant

• Current Assignee: Daewoong Pharmaceutical Company Limited, Green Cross Corporation (Green Cross Holdings Corporation)
• Original Assignee: Daewoong Pharmaceutical Company Limited
• Inventors: Yoon, Hee-kyoon, Park, Se-Hwan, Yoon, Ji-sung, Choi, Soongyu, Seo, Hee Jeong, Park, Eun-Jung, Kong, Younggyu, Song, Kwang-Seop, Kim, Min Ju, Park, So Ok
• Primary Examiner(s): Rahmani, Niloofar
• Application Number:
  US16/310,005
• Publication Number:
  US 20190169174A1
• Time in Patent Office: 1,055 Days
• Field of Search: 549414, 549356
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: B01D 9/005 Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
• CPC Class Codes: C07B 2200/13 Crystalline forms, e.g. polymorphs
• CPC Class Codes: C07B 51/00 Introduction of protecting groups or activating groups, not provided for in the preceding groups
• CPC Class Codes: C07D 307/78 Benzo [b] furans; Hydrogenated benzo [b] furans
• CPC Class Codes: C07D 407/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 409/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: Y02P 20/55 Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.

Claims

1. A crystalline form of a compound of the following Formula c28:

2. A crystalline form of a compound of the following Formula c28:

3. A crystalline form of a compound of the following Formula c28:

4. A crystalline form of a compound of the following Formula c28: